239 related articles for article (PubMed ID: 37508442)
1. PACAP and VIP Neuropeptides' and Receptors' Effects on Appetite, Satiety and Metabolism.
Vu JP; Luong L; Sanford D; Oh S; Kuc A; Pisegna R; Lewis M; Pisegna JR; Germano PM
Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508442
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP).
Vu JP; Larauche M; Flores M; Luong L; Norris J; Oh S; Liang LJ; Waschek J; Pisegna JR; Germano PM
J Mol Neurosci; 2015 Jun; 56(2):377-87. PubMed ID: 25904310
[TBL] [Abstract][Full Text] [Related]
3. Pituitary adenylate cyclase-activating polypeptide promotes eccrine gland sweat secretion.
Sasaki S; Watanabe J; Ohtaki H; Matsumoto M; Murai N; Nakamachi T; Hannibal J; Fahrenkrug J; Hashimoto H; Watanabe H; Sueki H; Honda K; Miyazaki A; Shioda S
Br J Dermatol; 2017 Feb; 176(2):413-422. PubMed ID: 27453364
[TBL] [Abstract][Full Text] [Related]
4. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus.
Matsuda K; Maruyama K; Nakamachi T; Miura T; Uchiyama M; Shioda S
Peptides; 2005 Sep; 26(9):1611-6. PubMed ID: 16112400
[TBL] [Abstract][Full Text] [Related]
6. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptides shaping the central nervous system development: Spatiotemporal actions of VIP and PACAP through complementary signaling pathways.
Maduna T; Lelievre V
J Neurosci Res; 2016 Dec; 94(12):1472-1487. PubMed ID: 27717098
[TBL] [Abstract][Full Text] [Related]
8. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Protects Striatal Cells and Improves Motor Function in Huntington's Disease Models: Role of PAC1 Receptor.
Solés-Tarrés I; Cabezas-Llobet N; Lefranc B; Leprince J; Alberch J; Vaudry D; Xifró X
Front Pharmacol; 2021; 12():797541. PubMed ID: 35153755
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
Vaudry D; Gonzalez BJ; Basille M; Yon L; Fournier A; Vaudry H
Pharmacol Rev; 2000 Jun; 52(2):269-324. PubMed ID: 10835102
[TBL] [Abstract][Full Text] [Related]
10. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
Hashimoto H
Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate.
Asnicar MA; Köster A; Heiman ML; Tinsley F; Smith DP; Galbreath E; Fox N; Ma YL; Blum WF; Hsiung HM
Endocrinology; 2002 Oct; 143(10):3994-4006. PubMed ID: 12239111
[TBL] [Abstract][Full Text] [Related]
12. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis.
Isobe K; Kaneko M; Kaneko S; Nissato S; Nanmoku T; Takekoshi K; Okuda Y; Kawakami Y
Regul Pept; 2004 Dec; 123(1-3):29-32. PubMed ID: 15518890
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.
Arimura A
Jpn J Physiol; 1998 Oct; 48(5):301-31. PubMed ID: 9852340
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
16. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
18. Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis.
Nussdorfer GG; Malendowicz LK
Peptides; 1998; 19(8):1443-67. PubMed ID: 9809661
[TBL] [Abstract][Full Text] [Related]
19. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.
Harmar AJ; Fahrenkrug J; Gozes I; Laburthe M; May V; Pisegna JR; Vaudry D; Vaudry H; Waschek JA; Said SI
Br J Pharmacol; 2012 May; 166(1):4-17. PubMed ID: 22289055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
